Clemson Rural Health, Guardian Research Network Partner to Improve Outcomes
Companies to collaborate on facilitating clinical trials in historically underserved regions.
Guardian Research Network (GRN) announced in a company press release that it has been joined by Clemson Rural Health to transform health outcomes in rural communities by conducting and facilitating clinical trials in historically underserved regions. GRN’s healthcare database is expected to help Clemson Rural Health bolster community health efforts to reduce premature mortality, decrease preventable hospitalizations and improve overall quality of life for local South Carolina patients.
"Partnering with Clemson Rural Health is a significant milestone for GRN," said Bruce Holstien, chairman, CEO, GRN. "Bringing this innovative team into our consortium demonstrates our unwavering commitment to improving access to cutting-edge studies in underserved communities. I look forward to the work we will accomplish together in our shared mission of driving community health advancements."
Reference: Clemson Rural Health Joins Forces with Guardian Research Network to Improve Community Health. PR Newswire. October 3, 2023. Accessed October 10, 2023. https://www.prnewswire.com/news-releases/clemson-rural-health-joins-forces-with-guardian-research-network-to-improve-community-health-301945161.html
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
